Imperial College London
Alternate

ProfessorNicholasGrassly

Faculty of Medicine, School of Public Health

Prof of Infectious Disease & Vaccine Epidemiology
 
 
 
//

Contact

 

n.grassly Website

 
 
//

Location

 

1102Sir Michael Uren HubWhite City Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Macklin:2020:10.1126/science.aba1238,
author = {Macklin, GR and O'Reilly, KM and Grassly, NC and Edmunds, WJ and Mach, O and Krishnan, RSG and Voorman, A and Vertefeuille, JF and Abdelwahab, J and Gumede, N and Goel, A and Sosler, S and Sever, J and Bandyopadhyay, AS and Pallansch, MA and Nandy, R and Mkanda, P and Diop, OM and Sutter, RW},
doi = {10.1126/science.aba1238},
journal = {Science},
pages = {401--405},
title = {Evolving epidemiology of poliovirus serotype 2 following withdrawal of the serotype 2 oral poliovirus vaccine},
url = {http://dx.doi.org/10.1126/science.aba1238},
volume = {368},
year = {2020}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Although there have been no cases of serotype 2 wild poliovirus for more than 20 years, transmission of serotype 2 vaccine-derived poliovirus (VDPV2) and associated paralytic cases in several continents represent a threat to eradication. The withdrawal of the serotype 2 component of oral poliovirus vaccine (OPV2) was implemented in April 2016 to stop VDPV2 emergence and secure eradication of all serotype 2 poliovirus. Globally, children born after this date have limited immunity to prevent transmission. Using a statistical model, we estimated the emergence date and source of VDPV2s detected between May 2016 and November 2019. Outbreak response campaigns with monovalent OPV2 are the only available method to induce immunity to prevent transmission. Yet our analysis shows that using monovalent OPV2 is generating more paralytic VDPV2 outbreaks with the potential for establishing endemic transmission. A novel OPV2, for which two candidates are currently in clinical trials, is urgently required, together with a contingency strategy if this vaccine does not materialize or perform as anticipated.
AU  - Macklin,GR
AU  - O'Reilly,KM
AU  - Grassly,NC
AU  - Edmunds,WJ
AU  - Mach,O
AU  - Krishnan,RSG
AU  - Voorman,A
AU  - Vertefeuille,JF
AU  - Abdelwahab,J
AU  - Gumede,N
AU  - Goel,A
AU  - Sosler,S
AU  - Sever,J
AU  - Bandyopadhyay,AS
AU  - Pallansch,MA
AU  - Nandy,R
AU  - Mkanda,P
AU  - Diop,OM
AU  - Sutter,RW
DO  - 10.1126/science.aba1238
EP  - 405
PY  - 2020///
SN  - 0036-8075
SP  - 401
TI  - Evolving epidemiology of poliovirus serotype 2 following withdrawal of the serotype 2 oral poliovirus vaccine
T2  - Science
UR  - http://dx.doi.org/10.1126/science.aba1238
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000528513300039&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - http://hdl.handle.net/10044/1/79887
VL  - 368
ER  -
Download